Clinical Trial

WEgovy Real World Assessment of Weight Loss in Korea

Enrolling by Invitation
View on ClinicalTrials.gov →
Summary
This study is to investigate the effectiveness and safety of Wegovy (semaglutide) in Korean patients living with obesity in routine clinical practice. The purpose of this study is to investigate the change in body weight and other clinical characteristics related to body weight in patients living with obesity. Participants will be treated with Wegovy (semaglutide) as prescribed by their doctor, in accordance with normal clinical practice. The study will last for about 52 weeks.
Trial Details
NCT Number NCT07280221
Lead Sponsor Novo Nordisk A/S
Conditions Obesity
Enrollment 500 participants
Start Date 2025-11-10
Primary Completion 2027-10-31 (estimated)
Study Completion 2027-10-31 (estimated)
Updated on ClinicalTrials.gov 2025-12-12